Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMaple-Brown, L.en
dc.contributor.authorLindenmayer, G.en
dc.contributor.authorBarzi, F.en
dc.contributor.authorWhitbread, C.en
dc.contributor.authorConnors, C.en
dc.contributor.authorMoore, E.en
dc.contributor.authorBoyle, J.en
dc.contributor.authorKirkwood, M.en
dc.contributor.authorLee, I.en
dc.contributor.authorLongmore, D.en
dc.contributor.authorvan Dokkum, P.en
dc.contributor.authorWicks, M.en
dc.contributor.authorDowden, M.en
dc.contributor.authorInglis, C.en
dc.contributor.authorCotter, M.en
dc.contributor.authorKirkham, R.en
dc.contributor.authorCorpus, S.en
dc.contributor.authorChitturi, S.en
dc.contributor.authorThomas, S.en
dc.contributor.authorO'Dea, K.en
dc.contributor.authoret al.en
dc.identifier.citationJournal of Diabetes, 2019; 11(9):1-10en
dc.description.abstractBACKGROUND:In Australia's Northern Territory, Indigenous mothers account for 33% of births and have high rates of hyperglycemia in pregnancy. The prevalence of type 2 diabetes (T2D) in pregnancy is up to 10-fold higher in Indigenous than non-Indigenous Australian mothers, and the use of metformin is common. We assessed birth outcomes in relation to metformin use during pregnancy from a clinical register. METHODS:The study included women with gestational diabetes (GDM), newly diagnosed diabetes in pregnancy (DIP), or pre-existing T2D from 2012 to 2016. Data were analyzed for metformin use in the third trimester. Regression models were adjusted for maternal age, body mass index, parity, and insulin use. RESULTS:Of 1649 pregnancies, 814 (49.4%) were to Indigenous women, of whom 234 (28.7%) had T2D (vs 4.6% non-Indigenous women; P < 0.001). Metformin use was high in Indigenous women (84%-90% T2D, 42%-48% GDM/DIP) and increased over time in non-Indigenous women (43%-100% T2D, 14%-35% GDM/DIP). Among Indigenous women with GDM/DIP, there were no significant differences between groups with and without metformin in cesarean section (51% vs 39%; adjusted odds ratio [aOR] 1.25, 95% confidence interval [CI] 0.87-1.81), large for gestational age (24% vs 13%; aOR 1.5, 95% CI 0.9-2.5), or serious neonatal adverse events (9.4% vs 5.9%; aOR 1.32, 95% CI 0.68-2.57). Metformin use was independently associated with earlier gestational age (37.7 vs 38.5 weeks), but the risk did not remain independently higher after exclusion of women managed with medical nutrition therapy alone, and the increase in births <37 weeks was not significant on multivariate analysis. CONCLUSIONS:We found no clear evidence of any adverse outcomes related to the use of metformin for the treatment of hyperglycemia in pregnancy.en
dc.description.statementofresponsibilityLouise J. Maple‐Brown, Greta Lindenmayer, Federica Barzi, Cherie Whitbread, Christine Connors ... Alex Brown ... et al.en
dc.rights© 2019 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.en
dc.subjectBirth outcomes; diabetes in pregnancy; gestational diabetes; metformin; type 2 diabetes in pregnancyen
dc.titleReal-world experience of metformin use in pregnancy: observational data from the Northern Territory Diabetes in Pregnancy Clinical Registeren
dc.typeJournal articleen
pubs.library.collectionObstetrics and Gynaecology publicationsen
dc.identifier.orcidBrown, A. [0000-0003-2112-3918]en
Appears in Collections:Obstetrics and Gynaecology publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.